Back to Search Start Over

280TiPGOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥ second-line recurrent or metastatic cervical cancer.

Authors :
Tewari, K S
Vergote, I
Oaknin, A
Alvarez, E
Gaillard, S
Lheureux, S
Rischin, D
Santin, A D
Feng, M
Mathias, M
Source :
Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Publication Year :
2018

Subjects

Subjects :
*METASTASIS
*CERVICAL cancer
*MEDICINE

Details

Language :
English
ISSN :
09237534
Volume :
29
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
133479077
Full Text :
https://doi.org/10.1093/annonc/mdy436.027
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details